IP Library Granted Patent US 8,063,047
Granted Patent B2
US 8,063,047 · App. 12/119,208 · Granted Nov 22, 2011

Pyridazine compounds and methods

Assignees: Centre National de la Recherche Scientifique (CNRS); Northwestern University; Universite de Strasbourg
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,063,047
App. No.
12/119,208
Granted
Nov 22, 2011
Kind
B2
Abstract

The invention relates to novel chemical compounds of Formula I compositions and methods of using the same. In particular, the invention provides pyridazine compounds and/or related heterocyclic derivatives, compositions comprising the same, and methods of using pyridazine compounds and/or related heterocyclic derivatives and compositions comprising the same, for modulation of cellular pathways (e.g., signal transduction pathways), for treatment or prevention of inflammatory diseases (e.g., Alzheimer's disease), for research, drug screening, and therapeutic applications.

Claims (15)

1. A compound of the formula I

wherein R 1 is a heterocyclic group which may have one or more substituents, R 2 is hydrogen, an alkoxy carbonyl or an alkylamino carbonyl, and R 3 is hydrogen or alkyl.

2. A compound of the formula I according to claim 1 wherein R 1 is pyrrolidinyl, imidazolidinyl, piperidinyl, or piperazinyl, each of which may be substituted.

3. A compound of the formula I according to claim 2 wherein the pyrrolidinyl, imidazolidinyl, piperidinyl, or piperazinyl group is substituted with heteroaryl, aryl, alkyl, or a heterocyclic group each of which may be substituted.

4. A compound of the formula I according to claim 2 wherein R 1 is piperazinyl substituted with a substituted or unsubstituted pyrimidinyl, pyridyl or pyridinyl; with aryl or substituted aryl; or with alkyl.

5. A compound of the formula I according to claim 1 wherein R 1 is piperazinyl substituted with pyrimidinyl, and R 2 is hydrogen, methoxy carbonyl, ethoxy carbonyl, isopropoxy carbonyl, t-butoxycarbonyl, t-pentyloxycarbonyl, or heptyloxy carbonyl, or alkylamino carbonyl, and R 3 is hydrogen.

6. A compound of the formula I according to claim 1 wherein R 1 is piperazinyl substituted with one or more of alkyl, phenyl, substituted phenyl, pyrimidinyl, substituted pyrimidinyl, or pyridinyl.

7. A pharmaceutical composition comprising a compound of the formula I according to claim 1 , and a pharmaceutically acceptable carrier, excipient, or vehicle.

8. A kit comprising one or more compounds of the formula I according to claim 1 for preventing and/or treating a disease, a container, and instructions for use.

9. A compound of the formula I:

wherein X and Y are each independently N or CH; or a pharmaceutically acceptable salt thereof.

10. A compound of claim 9 wherein X and Y are N.

11. A compound of claim 9 wherein X and Y are CH.

12. A compound of claim 9 wherein X is N and Y is CH.

13. A pharmaceutical composition comprising a compound of the formula I according to claim 9 , and a pharmaceutically acceptable carrier, excipient, or vehicle.

Assignments (2)
CONFIRMATORY LICENSE Recorded Dec 9, 2011
From: NORTHWESTERN UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 027358/0637 →
MERGER Recorded Mar 12, 2009
From: UNIVERSITE LOUIS PASTEUR (UNIVERSITE STRASBOURG I) "ULP"; UNIVERSITE MARC BLOCH (UNIVERSITE STRASBOURG II) "UMB"; UNIVERSITE ROBERT SCHUMAN (UNIVERSITE STRASBOURG III) "URS"
To: UNIVERSITE DE STRASBOURG
Reel/Frame 022382/0697 →
Continuity (4)
Continuation 11666872 · May 1, 2007
Provisional Application 60624346 · Nov 2, 2004
Provisional Application 60723376 · Oct 4, 2005
Related Publication 20090029985A1 · Jan 29, 2009